Bank Julius Baer & Co. Ltd Zurich Cuts Stake in Medpace Holdings, Inc. $MEDP

Bank Julius Baer & Co. Ltd Zurich lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 22.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,253 shares of the company’s stock after selling 1,217 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Medpace were worth $2,417,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mainsail Asset Management LLC acquired a new position in Medpace during the 4th quarter worth approximately $229,000. Oregon Public Employees Retirement Fund grew its holdings in Medpace by 0.9% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,460 shares of the company’s stock worth $2,505,000 after acquiring an additional 40 shares in the last quarter. Independent Advisor Alliance grew its holdings in Medpace by 37.4% during the 4th quarter. Independent Advisor Alliance now owns 1,434 shares of the company’s stock worth $805,000 after acquiring an additional 390 shares in the last quarter. Legacy Financial Advisors Inc. acquired a new position in Medpace during the 4th quarter worth approximately $290,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in Medpace by 2.8% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 5,589 shares of the company’s stock worth $3,139,000 after acquiring an additional 150 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms issued fresh reminders about an already filed class action alleging Medpace misled investors during the April 22, 2025 to February 9, 2026 period, with lead-plaintiff deadlines approaching in early June. Article Title
• Negative Sentiment: New and repeated class-action notices are keeping Medpace’s alleged investor-harm claims in the spotlight, which can weigh on sentiment and increase legal overhang for the stock. Article Title
• Negative Sentiment: Coverage specifically highlighting Medpace’s backlog disclosures and governance suggests investors are scrutinizing the quality of the company’s operational reporting, adding to uncertainty around future performance. Article Title
• Negative Sentiment: Additional law firm notices from Faruqi & Faruqi, The Gross Law Firm, BFA Law, Rosen, Pomerantz, DJS Law Group, and Schall keep the class action front and center, reinforcing a negative near-term narrative for MEDP. Article Title

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Medpace Trading Down 0.9%

Shares of Medpace stock opened at $415.27 on Friday. The company has a fifty day simple moving average of $463.68 and a 200-day simple moving average of $525.06. Medpace Holdings, Inc. has a 12-month low of $287.17 and a 12-month high of $628.92. The stock has a market cap of $11.86 billion, a price-to-earnings ratio of 26.10, a PEG ratio of 2.13 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the prior year, the business posted $3.67 EPS. The company’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on MEDP shares. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a report on Friday, February 13th. BMO Capital Markets lowered their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Robert W. Baird lowered their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Barclays lowered their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.